RFamide-related peptide 3 (RFRP3), the mammalian homologue of avian gonadotropin-inhibitory hormone, has been shown to negatively regulate the secretion of LH and may contribute to reproductive seasonality in some species. Herein, we examined the presence and potential role of the RFRP3-signaling system in regulating LH secretion in the mare during the breeding and nonbreeding seasons. Hypothalamic NPVF mRNA (the precursor mRNA for RFRP3) was detected at the level of the dorsomedial nucleus and paraventricular nucleus, but expression did not change with season. A greater number of RFRP3-expressing cells was observed throughout the rostralcaudal extension of the dorsomedial nucleus. Furthermore, adenohypophyseal expression of the RFRP3 receptor (NPFFR1) during the winter anovulatory season did not differ from that during either the follicular or luteal phases of the estrous cycle. When tested in primary adenohypophyseal cell culture or in vivo during both the breeding and nonbreeding seasons, neither equine nor ovine peptide sequences for RFRP3 suppressed basal or GnRH-mediated release of LH. However, infusion of RF9, an RFRP3 receptor-signaling antagonist, into seasonally anovulatory mares induced a robust increase in secretion of LH both before and following continuous treatment with GnRH. The results indicate that the cellular machinery associated with RFRP3 function is present in the equine hypothalamus and adenohypophysis. However, evidence for functionality of the RFRP3-signaling network was only obvious when an antagonist RF9 was employed. Because GnRH-induced release of LH was not affected by RF9, its actions may occur upstream from the gonadotrope to stimulate or disinhibit secretion of GnRH.
INTRODUCTION
Transition from the breeding to nonbreeding season in horses is characterized by a marked decline in synthesis and release of adenohypophyseal LH and the cessation of ovulatory cycles in the mare. However, photoperiod-driven signaling pathways in the hypothalamic-hypophyseal axis that underlie this process in the equine species have not been fully elucidated [1] . Limited studies by Alexander and Irvine [2] , utilizing the intercavernous sinus (ICS) cannulation technique, and others using hypothalamic push-pull perfusion [3] , have indicated that the secretion of GnRH is decreased during the winter anovulatory period, similar to that observed during the nonbreeding season of other seasonal breeders [4] . Moreover, when seasonally anovulatory mares are infused hourly [5, 6] or continuously [6] [7] [8] with native GnRH, anterior pituitary secretion of LH is increased. Follicular development follows increased circulating concentrations of LH, and spontaneous or induced ovulations occur at a high frequency. Thus, regulation of the secretion or action of GnRH at the gonadotrope appears to be one of the most important factors regulating seasonality in the mare.
A potential role for inhibitory neuropeptides in regulating seasonality has also been proposed [9, 10] . Theoretically, such neuropeptides would act by impairing GnRH neuronal activity or through direct suppression of secretion of LH by the gonadotrope. Tsutsui et al. [11] was the first to report the existence of a novel hypothalamic neuropeptide with inhibitory effects on secretion of LH in quail. The molecule contained a C-terminal LPLRFamide sequence and was named gonadotropin-inhibitory hormone (GnIH). Three RFamide-related peptides, RFRP1, RFRP2, and RFRP3, and two G-protein coupled receptors, GPR147/NPFFR1 and GPR74/NPFFR2, have been characterized in mammalian species. In several reports, RFRP3 has been shown to suppress the secretion of LH [12] [13] [14] [15] as well as adenohypophyseal responsiveness to GnRH in rats [13] [14] [15] . Thus, if RFRP3 regulates seasonality in mammals, it may do so in part by direct effects on the adenohypophysis. However, the role of RFRP3 in mammalian reproduction remains controversial because the number of reports showing functional effects has been offset by a considerable number of studies indicating little or no effect in rats, hamsters, and sheep [16] [17] [18] [19] [20] [21] . Neither the existence nor function of RFRP3 has been investigated in the mare, a long-day breeder with distinct seasonal regulation in the pattern of LH synthesis and secretion [1] . Experiments summarized herein addressed the hypotheses that the RFRP3 system is functionally active in controlling secretion of LH and reproductive seasonality in the mare.
MATERIALS AND METHODS
All the animal-related experiments were approved by the Institutional Agricultural Animal Care and Use Committee (IAACUC) of the Texas A&M University System.
RFRP3 Sequence, Synthesis, and Application
Using primers designed for the equine NPVF gene (the gene encoding RFRP3) and its predicted mRNA (GenBank accession number XM_001498848), a cDNA of approximately 420 bp produced from equine hypothalamic mRNA was cloned into a vector and sequenced. The partial equine NPVF cDNA is approximately 85% identical to the human NPVF mRNA sequence (Supplemental Fig. S1 ; all the Supplemental Data is available online at www.biolreprod.org). The predicted sequence of the preprotein encoding the equine RFRP (eRFRP) is approximately 75% identical to the human and ovine preprotein sequences. Greater homology is observed within the sequences encoding the RFRP1, 2, and 3 peptides (Supplemental Fig. S2 ). Based on predicted cutting sites of the preprotein, the eRFRP3 was predicted to contain the sequence Ile-Pro-Asn-Leu-Pro-Gln-Arg-Phe-NH 2 . A peptide containing this amino acid sequence was synthesized and used for studies reported herein. Peptide composition was validated by high-performance liquid chromatography and mass spectral analysis (98% purity and molecular weight of 983) by the manufacturer (Auspep Pty Ltd.). Doses of eRFRP3 used in the following experiments were established based on those used previously in other species such as sheep [13] , cattle [14] , and rats [16] .
Seasonal Expression of the NPVF Gene in the Mare (Experiment 1)
Animal model and experimental design. Twelve light horse mares (Quarter Horse and mixed breed) with histories of regular reproductive cycles were used to test the hypothesis that expression of the NPVF gene is increased during the nonbreeding season. Mares were healthy and had an average body condition score of 5 (range 4-6 on 1-9 scale; [22] ). Because the mares were donated from various sources, their exact ages were not available; however, based on dentition, they appeared to range from 5 to 15 yr of age. Reproductive status of the mares was confirmed before the beginning of the experiment by use of transrectal ultrasonography (absence of a corpora luteum [CL] and presence of small follicles) and determination of circulating concentrations of progesterone of ,1 ng/ml. Four mares were euthanized during the winter anovulatory season (December and January). The remaining eight mares were euthanized during the follicular (n ¼ 4) and luteal (n ¼ 4) phases of the estrous cycle within the natural breeding season (May-July). For the follicular phase of the cycle, transrectal ultrasonography was used to confirm the absence of CL and basal progesterone concentrations of ,1 ng/ml. For the luteal phase of the cycle, we confirmed the presence of a CL by ultrasonography and elevated serum concentrations of progesterone (9.5, 20.6, 19.3 , and 11.3 ng/ml, respectively). After euthanasia, a tissue block containing the hypothalamus was dissected, rapidly frozen in liquid nitrogen vapor, and stored at À808C. Coronal sections (20 lm) were cut on a cryostat, and a series of every 10th section was used for detection of NPVF precursor mRNA by isotopic in situ hybridization using procedures similar to those described previously [23] . A template containing a 405 bp sequence of the equine NPVF cDNA linked to RNA polymerase promoters was produced using procedures described previously [24] and used for 35 S-labeled riboprobe synthesis. Hybridization with sense probe was used as the control. The location of NPVF mRNA-containing neurons were identified under dark-and bright-field microscopy based on density of silver grains 53 above background density. Cell counts were performed in comparable sections within the paraventricular nucleus (PVN; five sections) and the dorsomedial nucleus of the hypothalamus (DMH; 10 sections) of each mare.
Hormone assays. Serum concentrations of progesterone were determined using a commercial radioimmunoassay (RIA) kit (Coat-A-Count; Siemens Healthcare) as reported previously from this laboratory [25] . All the samples were analyzed for progesterone in a single assay with a minimum detectable concentration of 0.1 ng/ml and a mean intraassay coefficient of variation (CV) of 6.3%.
Statistical analysis. The main effect of reproductive status on the number of cells containing NPVF mRNA was compared using the Proc GLM (general linear models) procedure of the Statistical Analysis System (SAS Institute Inc.). The source of the variation was the reproductive status.
Adenohypophyseal Expression of NPFFR1 (RFRP3 Receptor) Gene During the Breeding and Nonbreeding Seasons (Experiment 2) Animal model and experimental design. Adenohypophyses of mares used for experiment 1 were used to test the hypothesis that expression of GPR147 is increased during the nonbreeding season. Adenohypophyses were snap frozen in liquid nitrogen and stored at À808C. Cellular RNA was isolated from adenohypophyseal tissue and reverse transcribed to cDNA as described previously [26] . Real-time RT-PCR was performed to determine the abundance of NPFFR1 mRNA in the adenohypophysis of mares (experiment 1) during the winter anovulatory season (n ¼ 4; December and January) and during the follicular (n ¼ 4) and luteal (n ¼ 4) phases of the estrous cycle within the natural breeding season (May-July). An equine NPFFR1 cDNA was produced by reverse-transcriptase reaction of equine hypothalamic RNA and amplification by PCR using primers designed based on the equine genome database (UCSC Genome Browser database; http://genome.ucsc.edu/). The cDNA was inserted into the pGEM-T Easy vector (Promega) and sequenced. Sequencing of the cDNA indicated 100% identity to the equine NPFFR1 mRNA (GenBank accession number XM005602580). Primers used in the real-time RT-PCR analysis were designed based on the sequence of the equine NPFFR1 cDNA and encompassed the exon 2 of the receptor. The following primers were used for amplification of NPFFR1: 5 0 GTGCTCATCTTCCTCCTCTG CATG G 3 0 (forward); 5 0 GCATGTGCCGGTTCTTGAGCACG 3 0 (reverse). Expression of RPS20 (reference gene) was used to normalize NPFFR1 expression. The following primers were used for amplification of RPS20:
0 (reverse). Reactions were performed in triplicate for each cDNA sample as described previously [26] . Absence of primer-dimer amplification was verified by omission of template (no-template control) in the reaction. The presence of genomic DNA carryover was verified by including RNA preparations (no reverse transcriptase) in a reaction. Absence of nonspecific amplification was confirmed by estimation of melting temperature of the PCR products.
Statistical analysis. Real-time RT-PCR data were analyzed after normalizing mean gene expression to the reference gene RPS20 and transforming to the average expression of a reference sample using the relative quantification method (DDC t ). The main effects of reproductive status on mean fold change in NPFFR1 mRNA abundance were compared between the groups using the Proc GLM procedure of SAS. The source of the variation was the reproductive status.
Effects of RFRP3 on GnRH-Mediated Secretion of LH from Adenohypophyseal Cell Culture (Experiment 3) Animal model and experimental design. This experiment tested the hypothesis that RFRP3 can directly suppress secretion of LH by gonadotropes in primary cell cultures. Adenohypophyses were obtained from five light horse mares (Quarter Horse and mixed breed) after euthanasia during the winter anovulatory period, a time when RFRP3 is expected to have enhanced inhibitory actions [9, 10] . Because these mares were donated for use in this experiment, their exact ages were not known. However, based on dentition, their ages ranged from 5 to 10 yr. All the mares had a body condition score of 5 (good) on a 1-9 scale [22] . Because concentrations of LH are typically extremely low during the nonbreeding season [27] in mares, all the mares received Alzet osmotic pumps delivering GnRH (100 lg/h) for 12-18 days prior to euthanasia to stimulate synthesis of releasable stores of LH [6] . Unlike other mammalian species, GnRH receptors do not become down-regulated in the horse during continuous exposure to pharmacological amounts of GnRH [28] .
Adenohypophyseal cells were dispersed enzymatically, plated in 6-well plates containing 300 000 cells/well, and cultured in Dulbecco modified Eagle medium following procedures described previously [29] . On Day 4 (after the cells reached approximately 70% confluence), cells were incubated with media alone (control), media containing GnRH (10 À8 M) only (positive control), or media containing GnRH (10 À8 M) plus eRFRP3 (10 À6 , 10
À7
, 10
À8
À9
, or 10 À10 M) for 4 h. The eRFRP3 preparation was prepared by Auspep Pty Ltd. Each treatment was applied to at least three wells, and five independent replications were performed. Additional cells were also treated with GnRH (10 À8 M) plus ovine RFRP3 (10 À6 or 10 À9 M) for 4 h. The preparations were provided by Dr. Iain Clarke (manufactured by Auspep Pty Ltd.) and Dr. Terry Nett (manufactured by United Biochemical Research, Inc.). The preparation from Dr. Iain Clarke has been shown previously to inhibit the release of LH from ovine gonadotropes [13] . At the end of each 4-h incubation period, the culture media were harvested and stored at À208C.
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Hormone analyses. Concentrations of LH in media were analyzed by double antibody RIA, as validated previously in this laboratory [25] . A highly purified equine LH (AFP-5130A; National Hormone and Peptide Program [NHPP], Torrance, CA) preparation was used for both iodinated tracer and standards. An anti-equine LH antiserum (AFP-240580; NHPP, Torrance, CA) was used at a dilution of 1:120 000 and yielded 28.3% binding on average at zero dose. The sensitivity of the LH assays were 0.1 ng/ml, and the mean intraand interassay CVs were 7.2% and 3.7%, respectively.
Statistical analysis. Concentrations of LH determined in the media of culture replicates (three to four wells) were averaged for each treatment within each cell preparation (n ¼ 5 mares). The Proc GLM procedure of SAS was used to determine the main effects of RFRP3 treatment on differences in media concentrations of LH. Sources of variation were the treatments, replicates (cell preparation from each mare), and treatment x replicate interaction. The leastsquares means procedure was used to compare means if significant differences were detected.
In Vivo Effects of RFRP3 in Mares During the Breeding Season (Experiment 4)
Animal model and experimental design. Thirteen mature Quarter Horse mares were used to test the hypothesis that eRFRP3 can suppress secretion of LH in mares during the breeding season. All the mares were in excellent health, had a body condition score of 5 or 6 (good to excellent) on a 1-9 scale [22] and ranged in age from 3 to 12 yr. Normal estrous cycles were confirmed in all the mares before the start of the study by monitoring ovarian structures every other day using transrectal ultrasonography and by daily teasing with a stallion. On Day 7 after ovulation, as determined by transrectal ultrasonography, mares were treated intramuscularly with 10 mg/2 ml prostaglandin F 2a (Lutalyse; Pfizer) to cause luteolysis. The following day, the ICS of each mare was catheterized via the superficial facial vein as reported earlier from our laboratory [30] to facilitate detection of episodic release of LH. Mares were assigned randomly to one of two groups: control (n ¼ 6) or RFRP3 (n ¼ 7). The experiment was divided into three periods, representing the time before (periods 1 and 2) and after (period 3) intravenous (i.v.) treatment with a bolus injection of GnRH. Control mares received 3 ml (i.v.) saline every 10 min during all three periods (8 h). The RFRP3 group received saline every 10 min for 2 h (period 1) and 250 lg (i.v.) eRFRP3 in 3 ml saline every 10 min during both periods 2 (4 h) and 3 (2 h). Blood samples were collected at 5-min intervals during periods 1 and 2 (6 h) to characterize the episodic pattern of secretion of LH as reported earlier from our laboratory [31] . At the end of period 2 (Hour 6), all the mares were administered a single i.v. injection of 1 mg/2 ml GnRH, and ICS blood samples were collected at 15-min intervals for an additional 2 h (period 3). The eRFRP3 preparation used was the same as in experiment 3.
On the day of sampling, mares were heparinized (40 000 international units [IU] sodium heparin, i.v.) at the beginning of the sampling period, and cannulas were flushed with heparinized saline (1.5 ml; 300 IU/ml) after each sample was collected. Samples were placed into tubes containing 50 ll of a 5% ethylenediaminetetraacetic acid-heparin solution (10 000 IU/ml) to prevent coagulation, placed immediately on ice, and centrifuged for plasma collection every hour after harvesting. Plasma was stored at À208C until analysis of LH.
Hormone assays. Radioimmunoassay for LH was the same as for previous experiments. Mean intra-and interassay CVs were 6.8% and 5.8%, respectively.
Statistical analysis. Luteinizing hormone data were transformed to a threepoint rolling average to reduce background noise as described previously [31] . To be considered an episode of release of LH, the CVs of the ascending and the descending sides of putative episodes were required to be greater than the intraassay CV. Once the episodes were identified, the amplitude, frequency, and duration of each episode were determined. An expression for the area under the curve (AUC) for the concentrations of LH after GnRH treatment was determined by definite integral. Data were analyzed using the GLM procedure of SAS to test the effects of RFRP3 treatments on frequency, duration, and amplitude of the episodes and the effect of the GnRH challenge on the area under the LH curve. The statistical model for the repeated measures analyses included treatment as the main effect, the period or time by treatment, and mare within treatment as the error term to test the main effects.
Effects of RFRP3 in Seasonally Anovulatory Mares Treated Continuously with GnRH (Experiment 5)
Animal model and experimental design. The hypothesis was that RFRP3 could suppress the ability of GnRH to stimulate secretion of LH in the seasonally anovulatory mare. Six mature Quarter Horse mares in excellent body condition (5-6 on a 1-9 scale; [22] ) were used. Mares were in good health and had a history of normal estrous cycles during the preceding breeding season.
Before the start of the experiment, all the mares were confirmed as anovulatory by daily transrectal ultrasonography and analyses of serum progesterone concentrations for at least 1 mo. For the mares to be considered anovulatory, serum concentration of progesterone was required to be ,1 ng/ml during this period with no ovarian follicles .28 mm. All the mares were fitted with osmotic pumps designed to deliver 100 lg GnRH/h continuously for 7 days. As noted in experiment 3, this treatment has been shown repeatedly to stimulate the synthesis and secretion of LH in mares during the winter anovulatory period [6, 7, 32] . Mares were assigned randomly to a replicated Latin square design to receive saline or eRFRP3 (5 mg i.v.) in saline (same preparation as in experiments 3 and 4) on consecutive days, with a 24 h washout period between treatments. Mares were fitted with ICS catheters as described in experiment 4. Treatments were administered at time zero, and ICS blood samples were collected at 5 min intervals for 3 h followed by the postharvesting procedures described in experiment 4.
Hormone assays. Radioimmunoassay for LH was performed as described previously to assess the episodic pattern and mean concentrations of LH. Mean intra-and interassay CV were 10.8% and 10.3%, respectively. Hormone analysis for progesterone was the same as for previous experiments to assess concentrations of progesterone in the serum samples collected daily. All the samples were analyzed for progesterone in a single assay with minimum detectable concentration of 0.1 ng/ml. The mean intraassay CV for progesterone was 8.7%.
Statistical analysis. Because of low frequency of detectable episodes during the anovulatory season and variation in the ability to detect secretory episodes in some mares in this experiment, only mean concentrations of LH were analyzed statistically. The effect of treatments on concentrations of LH was analyzed utilizing the GLM procedure of SAS. The statistical model tested the effect of RFRP3 dose on mean concentrations of LH using the mare as the subject and period as the repeated variable.
Effects of RF9, an RFRP3 Receptor Antagonist, on Secretion of LH During the Winter Anovulatory Period (Experiment 6) Animal model and experimental design. As noted earlier, RFRP3 has been inconsistent in its ability to suppress secretion of LH in other animal models, such as sheep [20] . However, a selective antagonist for the NPFF receptor, RF9 (adamantanecarbonyl-ARG-Phe-NH2), first reported by Pineda et al. [15] , has been shown to act as a potent stimulator of LH release in both rodents and sheep [15, 20] . Therefore, we used RF9 to further assess functionality of the RFRP3 system in the equine model. Ten winter anovulatory, light horse mares (Quarter Horse, Paint, and mixed breed) in excellent health and with a history of normal estrous cycles during the preceding breeding season were used. Mares ranged in age from 3 to 19 yr (average ¼ 9.4) and had an average body condition score of 4.9 (range ¼ 4-7 on a 1-9 scale; [22] ). Mares were assigned randomly to one of two treatments: control or RF9 (n ¼ 5/treatment). The RF9 used in this experiment was synthesized by GeneCust Europe. On experimental Day 0, jugular blood samples were collected at 10-min intervals for 5 h beginning 1 h before treatment. Intravenous injections of saline or RF9 (0.2 mg/kg body weight) were administered at Hours 1, 2, and 3. Mares were then treated continuously with GnRH (100 lg/h) for 72 h via subcutaneous osmotic pumps as described earlier to stimulate adenohypophyseal synthesis of LH. On experimental Day 4 (12 h after pump removal), jugular blood samples were collected at 10-min intervals for 6 h beginning 1 h before treatment. Intravenous injections of saline or RF9 (0.4 mg/kg body weight) were administered at 1 and 2 h. A GnRH injection (250 lg, i.v.) was administered at Hour 4 to test adenohypophyseal responsiveness. Plasma was harvested and stored at À208C until determination of plasma LH concentrations using a previously validated equine LH RIA [25] .
Hormone analyses. Radioimmunoassay for LH was the same as for the previous experiments. Mean intraassay CV was 7.4%, with all the samples analyzed in one assay.
Statistical analysis. The GLM procedure of SAS was used to determine the main effects of RF9 treatment on plasma concentrations of LH. Sources of variation were treatment, period, and treatment 3 period interaction. The leastsquares means procedure was used to compare means when significant differences were detected. The AUC was calculated using the trapezoid rule, and the Proc t-test procedure of SAS was used to determine the main effects of GnRH-treatment on differences in plasma concentrations of LH.
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RESULTS
Seasonal Expression of the NPVF Gene in the Mare (Experiment 1)
Hypothalamic NPVF mRNA was detected within the DMH and PVN as depicted in Figure 1 
Effects of RFRP3 on GnRH-Mediated Secretion of LH from Adenohypophyseal Cell Culture (Experiment 3)
Adenohypophyseal cells cultured with GnRH increased (P , 0.0001) media concentrations of LH 7-fold (17.5 6 1.7 ng/ ml) compared to vehicle (2.6 6 0.3 ng/ml; Fig. 2 ). However, eRFRP3 failed to reduce adenohypophyseal responsiveness to GnRH at any dose tested, as concentrations of LH in eRFRP3-plus GnRH-containing media did not differ (P ! 0.18; Fig. 2 ) from the positive control media stimulated with GnRH alone. Furthermore, ovine RFRP3 preparations previously used to suppress adenohypophyseal responsiveness to GnRH in a dosedependent manner in ovine primary adenohypophyseal cell cultures were ineffective in equine adenohypophyseal cultures (Fig. 2) .
In Vivo Effects of RFRP3 in Mares During the Breeding Season (Experiment 4)
An episodic pattern of secretion for LH was observed in intensively collected ICS samples of control and RFRP3-treated mares (Fig. 3A) . None of the variables measured in control and RFRP3-treated mares differed during the first 2 h (period 1) before RFRP3 treatment (Table 1) . Moreover, treatment with RFRP3 (250 lg) every 10 min for 4 h before GnRH treatment (period 2) and continuing for 2 h after GnRH treatment (period 3) had no effect on any of the variables measured. Variables included mean concentration (P ¼ 0.35), frequency (P ¼ 0.23), amplitude (P ¼ 0.60), and duration (P ¼ 0.25) of LH secretory episodes during periods 1 and 2 ( Fig. 3A and Table 1 ) and the AUC for GnRH-induced release of LH during period 3 ( Fig. 3B and Table 1 ). Mares had been treated continuously with GnRH (100 lg/h) for 12-18 days before euthanasia and tissue collection to stimulate synthesis of LH by gonadotropes. Treatment with GnRH stimulated (P , 0.0001) secretion of LH in all the cases compared to vehicle control, but none of the RFRP3 preparations suppressed this response. Treatments were applied to at least three wells/replicate, and five independent culture replications were performed.
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Effects of eRFRP3 in Seasonal Anovulatory Mares Treated Continuously with GnRH (Experiment 5)
Clear episodic secretory patterns of LH were not detected in plasma samples collected from the ICS of control or RFRP3-treated mares following continuous infusion of GnRH (100 lg/ h). Intravenous administration of a single bolus dose (5 mg) of eRFRP3 did not (P ¼ 0.66) influence mean concentrations of LH (0.9 6 0.03 ng/ml) compared to control (0.8 6 0.03 ng/ml) mares.
Effects of RF9 on Secretion of LH During the Winter Anovulatory Period (Experiment 6)
On Day 0, mean pretreatment concentrations of LH in the control and RF9-treated group differed (P , 0.001). Therefore, the pretreatment mean was used as a covariate in the mixed model analysis and adjusted least-squares means are presented in Figure 4A . A treatment 3 period interaction (P , 0.001) remained, with RF9 inducing a robust and sustained increase (P , 0.0001) in circulating concentrations of LH relative to controls during the treatment period. Continuous GnRH infusion at 100 lg/h increased (P ¼ 0.001) mean concentrations of LH between Day 0 (0.21 6 0.03 ng/ml) and Day 4 (0.33 6 0.03 ng/ml) in both control and RF9-treated mares. On Day 4, mean pretreatment concentrations of LH did not differ. Again, RF9 caused a sustained increase (P ¼ 0.002) in circulating concentrations of LH relative to controls (Fig. 4B) . Acute i.v. treatment with GnRH induced LH release in both groups, but responsiveness to GnRH as determined by AUC (arbitrary units) did not differ (P ¼ 0.91) between the control (54.9 6 9.8) and RF9 (57.1 6 17.5) treatments.
DISCUSSION
The results of experiments presented herein indicate that the mare has genomic machinery for RFRP3 regulation of hypothalamic-adenohypophyseal function. However, expression of NPVF (ligand) and NPFFR1 (receptor) genes do not change with season or stage of the estrous cycle. Nonetheless, the RFRP3 receptor antagonist, RF9, creates robust stimulatory effects on secretion of LH during the nonbreeding season, a result that contrasts with the surprising inability of both the equine and ovine RFRP3 to inhibit secretion of LH in primary adenohypophyseal cell cultures and in vivo.
In initial experiments, we hypothesized that the number of neurons expressing NPVF in the hypothalamus of the mare would be elevated during the winter anovulatory period and luteal phase of the estrous cycle when photostimulation and circulating estradiol concentrations, respectively, are minimized. However, because changes in NPVF expression did not differ with season or reproductive phase, functional regulation of the RFRP3 system in the mare may be gated further   FIG. 3 . A) Pattern of LH secretion in two representative control (left panels) and two eRFRP3-treated mares (right panels) in experiment 4. Mares were treated with 3 ml (i.v.) saline every 10 min during the first 2 h (period 1) and either saline or eRFRP3 (250 lg/3 ml saline) every 10 min for the 4-h period that followed (period 2). Treatment with eRFRP3 had no effect on the concentration, frequency, or amplitude of secretory episodes of LH (see Table 1 for detailed comparisons). B) Mean concentrations of LH in control and RFRP3-treated mares in response to 1 mg (i.v.) GnRH during period 3 (see Table 1 for detailed comparisons). TABLE 1. Least-squares mean (6 SEM) concentrations of LH, frequencies, amplitudes, and durations of LH secretory episodes, and AUC for GnRHinduced release of LH in saline and RFRP3-treated mares (experiment 4). 
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downstream. This could potentially include posttranscriptional regulation, vesicular storage and exocytosis at neuronal terminals, and receptor availability and activity on target tissues. Both GnIH and its mammalian homologue, RFRP3, have been linked to the regulation of reproductive seasonality in other seasonal breeding species (avian, rodents, and ovine) with marked changes in GnIH/RFRP3 expression and peptide accumulation observed in the hypothalamus in response to changing photoperiod [11, 13, 33, 34] . During the photostimulatory periods of these species, estradiol concentrations fluctuate with follicular growth to communicate in a feedback fashion with the medial basal hypothalamus. Another member of the RFamide family, kisspeptin, acts in a contrasting manner to that of GnIH/RFRP3 and exhibits increased hypothalamic mRNA expression and peptide concentration under the influence of estradiol [35] ; however, the role of estradiol in regulating functions of the GnIH/RFRP3 system has not been fully elucidated [12, 36, 37] . As noted earlier, RFRP3 has been shown in several experiments to suppress the secretion of LH in rats, hamsters, sheep, and cattle [12] [13] [14] 18] as well as to directly reduce adenohypophyseal responsiveness to GnRH in a dose-dependent manner [12, 13, 38] . Based on results from cell culture studies [13, 16, 39, 40] , RFRP3 appeared to be able to regulate secretion of LH through direct inhibitory effects on gonadotropes. In addition, LHb and FSHb gene expression was reduced in GnRH-stimulated, ovine pituitary cells treated with RFRP3 [13] . Anatomical evidence in birds and mammals supports the functionality of this pathway [13, [41] [42] [43] . In sheep, cell bodies containing RFRP3 are located within the DMH and PVN, and anterograde tract tracing indicated that at least RFRP3 neuronal cell bodies located in the PVN project to the neurosecretory zone of the median eminence [13] . We have observed a similar anatomic pattern in the mare (data not shown). However, in our experiments, adenohypophyseal expression of NPFFR1 during the winter anovulatory season did not differ from that during either the follicular or luteal phases of the estrous cycle. Thus, the hypothesis that expression of NPFFR1 is up-regulated during the winter anovulatory season, and would serve to drive a seasonal reduction in gonadotrope responsiveness to GnRH and reduce circulating concentrations of LH, was not supported. Moreover, functional studies using primary anterior pituitary cell cultures failed to support the hypothesis that RFRP3 reduces the responsiveness of gonadotropes to GnRH in the mare because neither equine nor ovine RFRP3 reduced secretion of LH. These results are in contrast to those obtained with primary adenohypophyseal cell cultures from several other species, including rats [16] , poultry [39] , and sheep [13] .
In a subsequent series of in vivo experiments, we set out to determine if RFRP3, when administered peripherally, decreases circulating concentrations of LH during the follicular phase of the estrous cycle and in seasonally anovulatory mares pretreated with GnRH to stimulate synthesis of LH in gonadotropes. The results indicated that neither acute nor chronic administration of eRFRP3 at any dose tested, or ovine RFRP3 given as a large single dose, were able to suppress episodic release, mean concentration, or GnRH-induced release of LH in mares [44] . Earlier studies in male calves [14] and ovariectomized ewes [13] indicated that RFRP3 suppressed pulsatile release of LH. However, this is in contrast to other reports in which neither intracerebroventricular nor i.v. RFRP3 treatments suppressed secretion of LH in ewes [20] . A similar failure of RFRP3 to suppress LH has been reported in ovariectomized, estradiol-replaced rats [17] and ovariectomized prepubertal gilts [45] . Moreover, RFRP3 has been shown to be stimulatory in the Syrian [19] and Siberian [21] hamster that, similar to the mare, are long-day breeders. Therefore, the role of RFRP3 in mammals has remained controversial as a result of the variable ability of RFRP3 to influence secretion of LH. The inability to detect clear effects of RFRP3 in primary adenohypophyseal cell cultures and in vivo in the studies reported herein adds to the controversy. Given the variability in the RFRP3 effects noted from the literature (e.g., inhibitory, stimulatory, no effect), one could speculate that individual preparations of the peptide may, for reasons unknown to investigators, lack biological activity. However, because the last four amino acids at the amidated Cterminus confer functionality to the molecule [46, 47] and because this sequence is homologous for sheep, cattle, humans, and horses [12, 13] , it does not seem reasonable that the simple, unmodified peptide could have inhibitory effects in one study but not another using the same species. Thus, failure to show inhibitory effects of the full equine sequence in sheep or cattle would not, in and of itself, provide unequivocal evidence for lack of biological activity. As noted earlier, one of the ovine preparations tested in our experiments had been reported to Because pretreatment mean concentrations of LH differed (P , 0.001) between groups, they were used as a covariate in the mixed model analysis. Following this adjustment, there remained a significant (P , 0.001) treatment 3 period interaction, and posttreatment mean concentrations of LH were greater (P , 0.0001) in the RF9-treated than in the control group. Black arrows indicate times of saline or RF9 treatment (0.2 mg/kg). B) Adjusted least-squares mean concentrations of LH in control and RF9-treated mares on Day 4 after a 72-h subcutaneous infusion of GnRH (100 lg/h) in experiment 6. Mean pretreatment concentrations of LH did not differ. There was a significant (P , 0.01) treatment 3 period interaction, and mean posttreatment concentrations of LH were greater (P , 0.002) in the RF9-treated compared to the control group. Black arrows indicate times of saline or RF9 treatment (0.4 mg/kg).
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have inhibitory effects on LH secretion in sheep [13] . However, it was not inhibitory in our equine adenohypophyseal cell cultures. The second ovine preparation tested had not been shown previously to be effective in suppressing LH in sheep (T.M. Nett, personal communication) and was not effective in our experiment in mares. Finally, in several reported studies where RFRP3 had inhibitory effects on secretion of LH, the effects were often limited and short-lived [16] [17] [18] 48] . Taken together, it appears that the functions of RFRP3 and related RFamides are much more complex than initially anticipated.
Importantly, an additional approach for examining the RFRP3-signaling network became available with the development of a putatively selective antagonist for the NPFFR1 receptor, RF9 [49] . The latter has been shown to induce a potent release of LH in rats, mice, and sheep when administered centrally or peripherally [15, 20, 50] . In experiment 5, we tested the hypothesis that peripheral administration of RF9 would induce secretion of LH in the winter anovulatory mare. Similar to results obtained in rodents and ewes [15, 20, 50] , RF9 caused a marked increase in circulating concentrations of LH. Furthermore, when mares were pretreated for 72 h with GnRH to induce additional synthesis of LH in their seasonally depleted pituitaries, the selective antagonist remained stimulatory. However, RF9 did not appear to change anterior pituitary responsiveness to GnRH. Although the specific mechanisms through which RF9 stimulates secretion of LH remain to be determined, the possibility exists that it is acting directly at the level of the GnRH neuron. To date, data from all the species reported (avian, rodents, ovine, monkeys, and humans) have demonstrated GnIH/RFRP3-immunoreactive fibers in close proximity to GnRH neurons [9, 12, 40, [51] [52] [53] [54] . Furthermore, NPFFR1 is expressed in GnRH neurons in birds [48] and rodents [47] . Functional support for this hypothesis includes a reduction in firing activity [55] [56] [57] and immediate early gene expression in GnRH neurons [17] with administration of RFRP3. In addition, RFRP3/GnIH directly inhibited GnRH neuronal activity by hyperpolarizing the neuronal membrane through potassium ion conductance in dwarf gourami [56] leading to downstream reduction in LH synthesis and secretion.
Although RFRP3 appears to function through NPFFR1 expressed within both the hypothalamus and pituitary [38, 54] , functional variability associated with RFRP3 effects has resulted in continued uncertainty regarding its mechanism of action in mammals. It is well documented that in mammalian gonadotropes, GnRH receptor is coupled with G aq/11 to stimulate phospholipase C (PLC), resulting in the generation of inositol triphosphate and diacylglycerol [58] . These two components then activate protein kinase C (PKC) and trigger calcium mobilization to induce phosphorylation of mitogenactivated protein kinases (MAPK) [58] . Mechanisms proposed in mammals to transmit RFRP3 signal at the level of the gonadotrope rely in part on its apparent ability to inhibit intracellular calcium mobilization [13] , the primary GnRH receptor-induced signal for gonadotropin exocytosis [59, 60] . Phosphorylation of extracellular signal-regulated kinase (ERK-1/2) [61] , which inhibits gonadotropin gene expression [62] , is also activated. Thus, based on those reports, it appears that RFRP3 effectively reduces GnRH-induced gonadotropin synthesis and secretion.
In the mare, data failed to demonstrate any functional effects of RFRP3 in vivo or primary adenohypophyseal cell culture. However, the emergence of RF9 as an antagonist of RFRP3 receptor provides an additional approach for evaluating RFRP3 actions. It is possible that RF9 acts directly on GnRH neurons through NPFFR1 to antagonize RFRP3 effects. In fact, results indicate that the effects of RF9 are not on pituitary gonadotropes [15] because the effects of RF9 are blocked by GnRH antagonists [20, 63] . In accordance with previous observations, RF9 induced a robust and sustained release of LH when administered to the mare peripherally. Thus, because secretion of LH in mares was induced rapidly, RF9 likely acts centrally to stimulate, or disinhibit the secretion of GnRH. However, in a recent report involving the Gpr54 knockout mouse, reduced effects of RF9 on secretion of LH were observed, suggesting secondary effects of RF9 mediated through kisspeptin-signaling pathways [64] .
In conclusion, the current series of studies in the mare indicate that the cellular machinery associated with RFRP3 function is present in the equine hypothalamus and adenohypophysis, although no evidence emerged to support a seasonal regulation of gene expression for the hypothalamic peptide or its receptor in the pituitary. Thus, the functional role of RFRP3 during different reproductive states in the mare remains unclear. Nonetheless, using RF9, an RFRP3 receptor antagonist, we have provided the first evidence for functionality within the RFRP3-signaling network in the horse. The basis for the failure of RFRP3 itself to act in an inhibitory fashion on secretion of LH in these studies in the mare, as well as in several other studies involving different species, remains open to further investigation.
